Inhibition of polymorphonuclear leukocyte 5-lipoxygenase and platelet cyclooxygenase by α-(3,5-di-tert-butyl-4-hydroxybenzylidene)-γ-butyrolactone (KME-4), a new anti-inflammatory drug